These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 705407)

  • 41. Prolongation of the activated partial thromboplastin time associated with poor venipuncture technic.
    McPhedran P; Clyne LP; Ortoli NA; Gagnon PG; Sanders FJ
    Am J Clin Pathol; 1974 Jul; 62(1):16-20. PubMed ID: 4833734
    [No Abstract]   [Full Text] [Related]  

  • 42. Letter: Prothrombin-complex concentrates in liver disease.
    Lancet; 1975 Jul; 2(7926):188-9. PubMed ID: 49788
    [No Abstract]   [Full Text] [Related]  

  • 43. [Spontaneous hemorrhages in PTA deficiency].
    Mey U; Hesse P; Schanzenbach H
    Z Gesamte Inn Med; 1966 Sep; 21(18):572-5. PubMed ID: 5990728
    [No Abstract]   [Full Text] [Related]  

  • 44. High prevalence of abnormal preoperative coagulation tests in patients with adolescent idiopathic scoliosis.
    Ho WK; Baccala M; Thom J; Eikelboom JW
    J Thromb Haemost; 2005 May; 3(5):1094-5. PubMed ID: 15869617
    [No Abstract]   [Full Text] [Related]  

  • 45. Anticoagulation beyond direct thrombin and factor Xa inhibitors: indications for targeting the intrinsic pathway?
    van Montfoort ML; Meijers JC
    Thromb Haemost; 2013 Aug; 110(2):223-32. PubMed ID: 23739841
    [TBL] [Abstract][Full Text] [Related]  

  • 46. THE INTERACTION OF CONTACT PRODUCT AND FACTOR IX.
    CATTAN AD; DENSON KW
    Thromb Diath Haemorrh; 1964 Apr; 11():155-66. PubMed ID: 14167099
    [No Abstract]   [Full Text] [Related]  

  • 47. Interactions among Hageman factor (HG, Factor XII), plasma thromboplastin antecedent (PTA, Factor XI), plasma prekallikrein (PK, Fletcher factor) and high molecular weight kininogen (HMW-K, Fitzgerald factor) in blood coagulation.
    Saito H; Ratnoff OD
    Adv Exp Med Biol; 1979; 120B():61-70. PubMed ID: 517254
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lymphocyte populations in peripheral blood and in liver biopsy specimens from patients with acute and chronic hepatitis.
    Ferrau' O; Freni MA; Aiello A; Crino' M; Consolo F
    Hepatogastroenterology; 1981 Apr; 28(2):84-6. PubMed ID: 7216151
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Studies on the action of Hageman factor: evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent.
    RATNOFF OD; DAVIE EW; MALLETT DL
    J Clin Invest; 1961 May; 40(5):803-19. PubMed ID: 13739760
    [No Abstract]   [Full Text] [Related]  

  • 50. 2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis: Factor XI as a Target for New Anticoagulants.
    Weitz JI; Fredenburgh JC
    Arterioscler Thromb Vasc Biol; 2018 Feb; 38(2):304-310. PubMed ID: 29269514
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Examination of the plasma clotting activities--determination of contact factors XII, XI].
    Murakami M; Umeda T
    Rinsho Byori; 1969; 16():Suppl 16:66-74. PubMed ID: 5391587
    [No Abstract]   [Full Text] [Related]  

  • 52. Partial thromboplastin time in the presence of heparin: a rapid polybrene neutralization method.
    Israels ED
    Am J Clin Pathol; 1982 Mar; 77(3):321-4. PubMed ID: 6803572
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The possible role of platelets in bypassing the contact phase of blood coagulation.
    Walsh PN; Tuszynski GP; Greengard JS; Griffin JH
    Haematologia (Budap); 1984; 17(2):169-78. PubMed ID: 6534825
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transfusion-induced specific anti-factor XI inhibitor in a patient with previously unrecognized factor XI deficiency.
    Musclow CE; Amato D; Ofosu F; Armstrong AL; Abbott D
    Am J Clin Pathol; 1988 Mar; 89(3):418-22. PubMed ID: 3258118
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Activity of the contact substance in thromboplastin formation in the full-term newborn infant].
    Schettini F; Wierdis T; Lattanzi E; Violante N; Zimbalatti F
    Boll Soc Ital Biol Sper; 1966 Aug; 42(16):1058-60. PubMed ID: 5969468
    [No Abstract]   [Full Text] [Related]  

  • 56. [Lupus anticoagulant screening: comparison of 5 tests (author's transl)].
    Follea G; Ffrench P; Trzeciak MC; Dechavanne M
    Nouv Rev Fr Hematol (1978); 1981; 23(4):203-7. PubMed ID: 7312614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. THE INDUCTION OF PERMEABILITY-INCREASING ACTIVITY IN HUMAN PLASMA BY ACTIVATED HAGEMAN FACTOR.
    RATNOFF OD; MILES AA
    Br J Exp Pathol; 1964 Jun; 45(3):328-45. PubMed ID: 14173175
    [No Abstract]   [Full Text] [Related]  

  • 58. Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease.
    Kotronen A; Joutsi-Korhonen L; Sevastianova K; Bergholm R; Hakkarainen A; Pietiläinen KH; Lundbom N; Rissanen A; Lassila R; Yki-Järvinen H
    Liver Int; 2011 Feb; 31(2):176-83. PubMed ID: 21134109
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Method of purification and properties of anti-XIa (inhibitor of the contact product).
    Niemetz J; Nossel HL
    Thromb Diath Haemorrh; 1967 May; 17(3-4):335-48. PubMed ID: 5589293
    [No Abstract]   [Full Text] [Related]  

  • 60. The relevance of blood clotting tests in chronic aggressive hepatitis.
    Coccheri S; Gasbarrini G
    Scand J Gastroenterol Suppl; 1973; 19():97-101. PubMed ID: 4515645
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.